The associated markers and their limitations for the primary screening of HCV carriers in public health examination

Hepatology Research

Volumn 39, Issue 7, 2009, Pages 664-674

  Miyazaki, Teruo ^a,b   Honda, Akira ^a,b   Ikegami, Tadashi ^b   Hara, Takashi ^c   Saitoh, Yoshifumi ^b   Hirayama, Takeshi ^b   Doy, Mikio ^d   Matsuzaki, Yasushi ^a,b,e  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Ibaraki pref   (Japan)

^c Ibaraki Prefectural Institute of Public Health   (Japan)

^d IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^e NONE   (Japan)

Author keywords

Aminotransferases; HCV; Health examination

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FEMALE; HEMATOLOGY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PUBLIC HEALTH; RECEIVER OPERATING CHARACTERISTIC; SPHYGMOMANOMETER; VIRUS CARRIER;

EID: 67649598625     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00513.x     Document Type: Article

References (32)

1. World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board. Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
2. Conry-Cantilena C, Van Raden M, Gibble J et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-6.
3. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: Patients with normal aminotransferase levels. Hepatology 1997; 26: 133S-6S.
4. Tassopoulos NC. EASL International Consensus Conference on Hepatitis C. Paris, 26-28 February 1999: Consensus statement. J Hepatol 1999; 30: 956-61.
5. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36: S179-84.
6. Shiffman ML, Diago M, Tran A et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006; 4: 645-52.
7. Puoti C, Magrini A, Stati T et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393-8.
8. Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
9. Okanoue T, Makiyama A, Nakayama M et al. A follow-up study to determine the value of liver biopsy and the need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 2005; 43: 599-605.
10. Piton A, Poynard T, Imbert-Bismut F et al. Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998; 27: 1213-19.
11. Okanoue T, Yasui K, Sakamoto S et al. Circulating HCV-RNA, HCV genotype, and liver histology in asymptomatic individuals reactive for anti-HCV antibody and their follow-up study. Liver 1996; 16: 241-7.
12. Okanoue T, Itoh Y, Minami M et al. Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatol Res 2008; 38: 27-36.
13. Tsukuma H, Tanaka H, Ajiki W, Oshima A. Liver cancer and its prevention. Asian Pac J Cancer Prev 2005; 6: 244-50.
14. Tanaka J, Yoshizawa H. Screening for liver cancer and hepatitis. In: Hisamichi S, ed. Task Force Report: Evaluation on Effectiveness of New Cancer Screening Techniques. Tokyo: Japan Public Health Association, 2001; 325-62.
15. Bray GA. Pathophysiology of obesity. Am J Clin Nutr 1992; 55: 488S-94S.
16. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.
17. Zechini B, Pasquazzi C, Aceti A. Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: The role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol 2004; 16: 891-6.
18. Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol 2000; 95: 1545-50.
19. Puoti C. HCV carriers with persistently normal ALT Levels: Not too much healthy, not true patients. Rom J Gastroenterol 2004; 13: 329-32.
20. Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: Alanine aminotransferase ratio in chronic hepatitis C infection: Is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000; 15: 386-90.
21. Anderson FH, Zeng L, Rock NR, Yoshida EM. An assessment of the clinical utility of serum ALT and AST in chronic hepatitis C. Hepatol Res 2000; 18: 63-71.
22. Schiavon LL, Narciso-Schiavon JL, Carvalho Filho RJ et al. Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. J Viral Hepat 2008; 15 (9): 666-74.
23. Cuccherini B, Nussbaum SJ, Seeff LB, Lukacs L, Zimmerman HJ. Stability of aspartate aminotransferase and alanine aminotransferase activities. J Lab Clin Med 1983; 102: 370-6.
24. Bartos V, Krkoska D, Slavik P, Lauko L, Adamkov M. Histological status of the liver in relation to serum aminotransferase levels in patients with chronic hepatitis C. Bratisl Lek Listy 2007; 108: 522-5.
25. Puoti C, Castellacci R, Montagnese F et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: The Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002; 37: 117-23.
26. Puoti C, Magrini A, Filippi T, Annovazzi G, Pannullo A, Rosci L. Prevalence of anti-hepatitis C virus antibodies among patients hospitalized in a medical unit. Eur J Gastroenterol Hepatol 1994; 6: 731-2.
27. Puoti C, Castellacci R, Montagnese F. Hepatitis C virus carriers with persistently normal aminotransferase levels: Healthy people or true patients? Dig Liver Dis 2000; 32: 634-43.
28. Yuki N, Hayashi N, Kamada T. HCV viraemia and liver injury in symptom-free blood donors. Lancet 1993; 342: 444.
29. Shindo M, Arai K, Sokawa Y, Okuno T. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995; 22: 418-25.
30. Ohkoshi S, Tawaraya H, Kuwana K et al. A retrospective study of hepatitis C virus carriers in a local endemic town in Japan. A possible presence of asymptomatic carrier. Dig Dis Sci 1995; 40: 465-71.
31. Gervais A, Bacq Y, Bernuau J et al. Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol 2000; 32: 293-9.
32. Guattery JM, Faloon WW, Biery DL. Effect of ethinyl estradiol on chronic active hepatitis. Ann Intern Med 1997; 126: 88.